Glyconjugate Vaccines
US-2024382585-A1 · Nov 21, 2024 · US
Selectively disrupted whole-cell vaccine
US9827299B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9827299-B2 |
| Application number | US-201013500925-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 12, 2010 |
| Priority date | Oct 9, 2009 |
| Publication date | Nov 28, 2017 |
| Grant date | Nov 28, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides for immunogenic compositions and methods for producing an immunogenic composition with multiple immunity-inducing fractions of killed, whole-cell Streptococcus pneumoniae by selectively disrupting a whole cell bacterial preparation in such a manner that a soluble fraction that induces a primarily antibody response, and a cellular fraction that induces a primarily antibody-independent response, remain in the immunogenic composition.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for producing a killed, whole-bacterial immunogenic composition from Streptococcus pneumoniae which elicits an antibody-mediated immune response and a T-lymphocyte mediated immune response, comprising (i) selectively disrupting the Streptococcus pneumoniae bacteria in a bacterial preparation into a soluble fraction and an insoluble fraction using a solvent that is at least one of: an immiscible solvent, a volatile agent which evaporates at room temperature, or beta-propiolactone whereby the solvent maintains the overall structure of the Streptococcus pneumoniae bacterial cell, (ii) removing the solvent by evaporation, hydrolysis or lyophilization or heat inactivation at 37° C. such that the soluble fraction is not removed from the bacterial preparation and both the soluble and cellular fraction remain in the immunogenic composition and wherein the bacterial cell preparation is not washed; (iii) resuspending the bacterial preparation in an aqueous solution comprising an adjuvant, wherein the soluble fraction elicits an antibody-mediated immune response, and the cellular fraction elicits a T-lymphocyte mediated immune response. 2. The method according to claim 1 , wherein said soluble fraction induces a serotype-independent antibody response, and said cellular fraction induces increased phagocytosis. 3. The method according to claim 1 , wherein the immiscible solvent or volatile agent which evaporates at room temperature is chloroform or trichloroethylene. 4. The method according to claim 1 , wherein the adjuvant is Al(OH) 3 or aluminum phosphate.
Assignees
Inventors
Classifications
Bacterial toxins · CPC title
Inorganic adjuvants · CPC title
inactivated (killed) · CPC title
Immunostimulants · CPC title
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9827299B2 cover?
- The present invention provides for immunogenic compositions and methods for producing an immunogenic composition with multiple immunity-inducing fractions of killed, whole-cell Streptococcus pneumoniae by selectively disrupting a whole cell bacterial preparation in such a manner that a soluble fraction that induces a primarily antibody response, and a cellular fraction that induces a primaril…
- Who is the assignee on this patent?
- Malley Richard, Anderson Porter, Lu Yingjie, and 9 more
- What technology area does this patent fall under?
- Primary CPC classification A61K39/092. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).